Immunitybio Inc Strategic Asset Allocation Index
Immunitybio Inc strategic asset allocation index. Immunitybio Inc (IBRX) has a Strategic Asset Allocation Index of 40.7% as of June 2020. Strategic assets (PP&E of $69.02 Million plus long-term investments of $-) total $69.02 Million, measured against net assets of $169.65 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check IBRX goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of Immunitybio Inc (2016–2019)
Strategic asset allocation index of Immunitybio Inc from 2016 to 2019. This chart shows how Immunitybio Inc's Strategic Asset Allocation Index has evolved across 4 annual periods from 2016 to 2019. As of June 2020, the index stands at 40.7%, representing strategic assets of $69.02 Million against net assets of $169.65 Million USD.
Immunitybio Inc Strategic Asset Allocation Index by Year (2016–2019)
Immunitybio Inc strategic asset allocation index by year from 2016 to 2019. The table below presents the year-by-year Strategic Asset Allocation Index for Immunitybio Inc from 2016 to 2019, covering 4 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see IBRX company net worth.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2019 | 23.0% | $27.78 Million | $27.78 Million | $- | $120.68 Million | ▲ +2.7 pp |
| 2018 | 20.3% | $29.63 Million | $29.63 Million | $- | $146.01 Million | ▼ -14.8 pp |
| 2017 | 35.1% | $76.73 Million | $76.73 Million | $- | $218.84 Million | ▲ +28.5 pp |
| 2016 | 6.6% | $19.38 Million | $19.38 Million | $- | $293.42 Million | — |